Allergan vet Ingram takes the helm at Sarepta; Big Pharma alumni Catherine Steele is the new comms chief at Biogen
→ Ed Kaye will now be transitioning out of Sarepta, as planned. The board announced this week that Doug Ingram will be taking over the Duchenne muscular dystrophy company. Ingram is the former president of Allergan, stepping out after the big merger with Actavis. He then went to run Chase, and sold the Alzheimer’s company to Allergan. Now he’ll be in charge of expanding sales for Sarepta’s Exondys 51 and running the pipeline as analysts speculate whether another M&A deal could be in the works.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.